Clinical Trial Update: Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial compares pemetrexed alone versus pemetrexed plus erlotinib in nonsquamous non-small cell lung cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)
• Tarceva (erlotinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. | Phase 2 | Status: COMPLETED | Results posted: 2011-10-13